vinblastine / Generic mfg. - LARVOL DELTA

Mitotic error-tolerant survival following WRN inhibition is overcome by sustained spindle checkpoint activation (AACR 2026) - "Based on our findings, we identified a previously unrecognized mitotic error-tolerant survival pathway induced by WRN inhibition. We further demonstrated that Vinblastine, by sustaining spindle checkpoint activation, synergized with WRN inhibition to reduce cell viability and suppress escape mechanism. These results suggest that combining MTA with WRN inhibitors represents a promising therapeutic strategy in MSI-H cancers."

Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • CCNB1 • MSI • WRN

Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (AACR 2026) - "Cross-model validation identified state-specific candidate drugs, including Leuprolide, Vinblastine, and Mercaptopurine for GLS; Vindesine, Gossypol, and Binimetinib for MOS; and AT9283, Crizotinib, and Afatinib for PLS. Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC."

Oncology • Pancreatic Ductal Adenocarcinoma • APOE

Exploring the impact of RAS mutations in abdominopelvic Rosai Dorfman disease on responsiveness to targeted therapies: A case control study (AACR 2026) - "All 4 patients received frontline cobimetinib with 3 achieving at least a partial response and two demonstrating near-complete resolution of all known disease sites...One patient eventually progressed during dose reduction and was transitioned to trametinib; another passed from non-RDD cardiac causes.We also reviewed an age-matched cohort (63-79) of 4 patients with abdominopelvic RDD lacking baseline RAS/MAPK pathway or other driver mutations...Management strategies varied as only two patients received frontline systemic therapy, one sequentially with bexarotene followed by rituximab and the other with vinblastine... Patients with RAS-mutated abdominopelvic RDD tend to experience a more aggressive disease course compared to wildtype but demonstrate marked sensitivity to MAP Kinase pathway-targeting therapies. The findings of this study are limited by small sample size; ongoing efforts are underway to expand with a multi-center cohort."

Clinical • Oncology • CD163 • CD68 • DNMT3A • KRAS • NRAS • RAS • RTEL1

A novel potent tetrahydroisoquinoline analog: A cytostatic taxol-like agent (AACR 2026) - "In 2024, according to the American Chemical Society, approximately 310,720 new cases of invasive breast cancer will be diagnosed among US women, and 42,250 women will die from breast cancer. MG-KRR-5-268 (257nM) exhibited strong prevention of spheroid compaction across submicromolar doses, phenocopying the disassembly of the vinblastine phenotype through a non-tubulin mechanism, compared to the other THIQ analogs. These findings highlighted MG-KRR-5-268 acted as the most potent compound with a novel capacity to prevent 3D tumor solidification through transcriptome reprogramming rather than microtubule binding."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (EBMT 2026) - "All patients were treated with combination of nivo (3 mg/kg or 40 mg every 2 weeks) and chemo- or targeted therapy: bendamustine 90 mg/m² D1,2 of a 28-day cycle (n=55), vinblastine 10 mg every 2 weeks (n=42), brentuximab vedotin (BV) 1.8 mg/kg every 3 weeks (n=20), or gemcitabine 800-1000 mg every 2 weeks (n=6). The use of combination regimens with CPI represents an effective and safe strategy. This approach is beneficial for patients who have failed multiple therapy lines including CPI, including its use as a bridge to allo-HCT, as well as for patients who are not candidates for transplantation."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation

FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (EBMT 2026) - "All patients were treated with combination of nivo (3 mg/kg or 40 mg every 2 weeks) and chemo- or targeted therapy: bendamustine 90 mg/m² D1,2 of a 28-day cycle (n=55), vinblastine 10 mg every 2 weeks (n=42), brentuximab vedotin (BV) 1.8 mg/kg every 3 weeks (n=20), or gemcitabine 800-1000 mg every 2 weeks (n=6). The use of combination regimens with CPI represents an effective and safe strategy. This approach is beneficial for patients who have failed multiple therapy lines including CPI, including its use as a bridge to allo-HCT, as well as for patients who are not candidates for transplantation."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation

Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study. (PubMed, Scand J Urol) - P=N/A | "This study reports current RC practices amongst Nordic countries. Patient cohorts did not differ between countries, and although the practices were generally similar, some differences were noted in chemotherapy regimens, the use of robotic-assisted surgery and rates of early RC."

Clinical • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. (PubMed, Lancet Haematol) - P1/2 | "Brentuximab vedotin-AVD was highly active and had a tolerable adverse event rate in HIV-cHL and is an important therapeutic option for people with HIV-cHL. The complete reponse rate is encouraging and is possibly related to a unique aspect of HIV-cHL biology. Upcoming 5-year data will evaluate the sustainability of the outcomes obtained."

Journal • P1/2 data • P2 data • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • CD4 • CYP3A4

Characterization and hemocompatibility of poly (N-acryloyl-L-tryptophan) nanoparticles as targeting delivery carriers for vinblastine. (PubMed, J Biomater Appl) - "More importantly, NPs-PEG-FA had good biocompatibility to L929 mouse fibroblast cells and exhibited hemocompatibility via the assays of hemolysis, antithrombogenicity, coagulation activation and platelet activation. NPs-PEG-FA could serve as drug carriers for delivering drugs into FR positive tumor cells."

Journal • Hematological Disorders • Oncology

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). (PubMed, J Clin Oncol) - "Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point was not met, but 17% of all enrolled patients and 48% of the AS group avoided cystectomy without metastatic disease."

Journal • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer • ERCC2 • FANCC • RB1

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) (ASH 2025) - "We assessed PROs in S1826, a trial showingthat nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Trial results support the feasibility ofserial collection of PROs, as indicated by high response rates, despite participants' advanced stagedisease and broad institutional participation. Future analyses will address the planned 3-year outcomesas well as formal evaluation of missing data."

Clinical • Metastases • P3 data • Patient reported outcomes • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. (PubMed, Eur Urol Oncol) - P3 | "We identified four factors prognostic for OS for patients with MIBC treated with NAC in VESPER. Basal molecular subtype was the most significant prognostic factor for OS, as it was independent of the treatment arm, and showed high prognostic value, in particular during the first year after randomization."

Biomarker • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Hodgkin Variant Richter's Transformation in the Absence of Classical Risk Factors: A Rare Case With Spinal Manifestation. (PubMed, Cureus) - "After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion."

Journal • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH • TP53

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. (PubMed, Eur Urol) - "These findings suggest that chemoimmunotherapy is a very promising approach for MIBC with histology subtypes. Larger studies are warranted to further refine therapeutic strategies."

IO biomarker • Journal • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Sarcoma • Solid Tumor

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Merck Sharp & Dohme Corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: Merck Sharp & Dohme Corp.

New P2 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov) - P2 | N=440 | Recruiting | Sponsor: Merck Sharp & Dohme Corp. | Trial completion date: Nov 2023 ➔ Feb 2027 | Trial primary completion date: Nov 2023 ➔ Feb 2027

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov) - P2 | N=340 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Hemophagocytic Lymphohistiocytosis Triggered by Hodgkin Lymphoma (SCCM 2026) - "She received Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy and steroids; etoposide was withheld due to instability. Studies show etoposide use improves remission and survival, whereas delays or omission worsen outcomes. Early empiric HLH‑directed therapy, ideally before organ failure, and multidisciplinary management, including nutritional optimization, are essential for improving survival."

Cachexia • Dyslipidemia • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Hodgkin Lymphoma • Hypertriglyceridemia • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Rare Diseases • Renal Disease • Respiratory Diseases • Septic Shock

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study. (PubMed, Fr J Urol) - "In this real-world study, incomplete TURBT and a history of NMIBC were independently associated with a lower pathological response to NAC, highlighting the importance of thorough initial tumor management. After 2022, favorable adherence to ddMVAC was observed without an apparent increase in severe toxicities in our cohort."

Journal • Real-world evidence • Retrospective data • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia